NCT06856850 · ACTIVE NOT RECRUITING
Disease Biosignatures in ALS/FTD Spectrum: New Impactful Biological Perspectives Beyond Clinical Approaches
This study looks for biological markers in easily accessible tissues that could help diagnose ALS and frontotemporal dementia and track how they progress. Researchers use gene, protein and other analyses, plus a test for a misfolded protein called TDP-43. No drug is given. The phase is unspecified. Details are limited so far.
You may qualify if
- Clinical criteria for ALS (Brooks et al., 2000; de Carvalho M., 2008), FTD (GornoTempini et al., 2011; Rascovsky et al., 2011)
You're excluded if
- na
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-08-28